Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68 PSMA R2 - Advanced Accelerator Applications

Next Previous
Drug Profile

Gallium-68 PSMA R2 - Advanced Accelerator Applications

Alternative Names: 68Ga-PSMA-R2; Ga68-PSMA-R2

Latest Information Update: 25 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University
  • Developer Advanced Accelerator Applications
  • Class Antineoplastics; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 15 Dec 2020 Phase-II clinical trials in Prostate cancer (Diagnosis) in USA (unspecified route) (NCT03698370)
  • 20 Aug 2019 Advanced Accelerator Applications completes the phase I/II PROfind trial for Prostate cancer (Diagnosis, Hormone refractory, Metastatic disease) in USA (NCT03490032)
  • 05 Feb 2019 Advanced Accelerator Applications re-initiates the phase I/II PROfind trial for Prostate cancer in USA (NCT03490032)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top